Ignite Creation Date:
2024-05-05 @ 10:47 PM
Last Modification Date:
2024-10-26 @ 10:23 AM
Study NCT ID:
NCT01182649
Status:
COMPLETED
Last Update Posted:
2010-08-17
First Post:
2010-08-09
Brief Title:
Everolimus Stent in Patients With Coronary Artery Disease CAD
Sponsor:
San Giuseppe Moscati Hospital
Organization:
San Giuseppe Moscati Hospital
Study Overview
Official Title:
Randomized Comparison of Everolimus Eluting Stents and Sirolimus Eluting Stent in Patients With Coronary Artery Disease
Status:
COMPLETED
Status Verified Date:
2010-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
RACES
Brief Summary:
Aim of the study is to compare the everolimus eluting stent and sirolimus eluting stent in all comers PCI eligible patients
Detailed Description:
Compared with the currently available first-generation drug-eluting stents DES second-generation DES have been designed with the goal of improving safety and efficacy Everolimus a sirolimus analogue is released from a open cell thin-strut cobalt-chromium frame A significant reduction in cardiac events was noted in patients with the everolimus-eluting stent compared with those who had a paclitaxel-eluting stent Sirolimus eluting stent was the first available drug eluting stent and is the most tested Therefore the investigators compared the safety and efficacy of the everolimus-eluting and sirolimus eluting stents in unselected patients in real world practice
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None